Video-on-Demand Library

26 February 2024

Min-Hua Jen, Antonio Remiro-Azocar, Anja Schiel, Suzy Van Sanden

Randomised controlled trials (RCTs) have been the gold standard for the evaluation of efficacy and safety of medical interventions. However, investigators have incentives to look for alternative ways to obtain relevant comparative effect estimates more rapidly for healthcare decision makers. The EUnetHTA 21 methodological guidelines will be officially finalised late in 2024 and will impact the statistical approaches used to obtain these effect estimates. Indirect treatment comparisons (ITCs) for the joint clinical assessment (JCA) require the estimation of comparative effectiveness via non-randomised designs.

Statisticians must be prepared for the changes this guidance will require. Indirect treatment comparisons should be considered a fundamental tool in the pharmaceutical statistician's toolbox, alongside other commonly used statistical techniques in the industry.

This webinar aims to provide information on the purpose and methods for ITC. The speakers will review and compare different approaches for ITC in both anchored and unanchored case. Both drug regulatory and reimbursement body’s views on using ITC will be discussed. The speakers will offer insights into issues such as marginal and conditional effect, unmeasured confounding and provide case studies to demonstrate the use of ITC methods in practice. 

Day 1, 26th February 2024: Indirect treatment comparison for anchored setting

  • Antonio Remiro-Azocar (Bayer) - Marginal versus conditional estimands, non-collapsibility and standardization in the context of indirect treatment comparisons
  • Anja Schiel (Norwegian Medical Products Agency (NoMA) - ITC’s applicability and acceptability in the European HTA landscape
  • Suzy Van Sanden (Johnson & Johnson) - Matching-adjusted indirect comparison (MAIC): A case studies in prostate cancer
  • Panel discussion

Part of Collection(s)


Upcoming Events

Latest Jobs